Latest Pharma Insights
Sandoz Mulls Appeal As US Court Dismisses Amgen Enbrel Antitrust Complaint
Sandoz has told Generics Bulletin that it is mulling further options, including an appeal, after a US court dismissed its antitrust complaint against Amgen over Enbrel. Currently, Sandoz’s Erelzi etanercept biosimilar – approved almost a decade ago – is blocked from launch for a further three years.
Generics Bulletin - February 20, 2026
Sandoz has told Generics Bulletin that it is mulling further options, including an appeal, after a US court dismissed its antitrust complaint against Amgen over Enbrel. Currently, Sandoz’s Erelzi etanercept biosimilar – approved almost a decade ago – is blocked from launch for a further three years.
Generics Bulletin - February 20, 2026
Kymriah To Country Music: Prof. Bruce Levine’s Unwavering CAR-T Focus
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Scrip - February 20, 2026
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Scrip - February 20, 2026
Novartis Signs Out Of Listed India Arm, ChrysCapital Taking Charge
Novartis divests listed India entity but maintains country commitment intact, portfolio expansions underway.
Scrip - February 20, 2026
Novartis divests listed India entity but maintains country commitment intact, portfolio expansions underway.
Scrip - February 20, 2026
Japan Recommends Global-First Conditional Approvals Of Two iPSC Therapies
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.
Scrip - February 20, 2026
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.
Scrip - February 20, 2026
US FDA’s Push For Greater Transparency: What About Advisory Committees?
Posting action packages for rejected products, not just the complete response letters, is a provocative idea, but also a reminder of what the FDA has lost by not holding many advisory committees during the Trump Administration.
HBW Insight - February 20, 2026
Posting action packages for rejected products, not just the complete response letters, is a provocative idea, but also a reminder of what the FDA has lost by not holding many advisory committees during the Trump Administration.
HBW Insight - February 20, 2026
Kymriah To Country Music: Prof. Bruce Levine’s Unwavering CAR-T Focus
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Scrip - February 20, 2026
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Scrip - February 20, 2026
Novartis Signs Out Of Listed India Arm, ChrysCapital Taking Charge
Novartis divests listed India entity but maintains country commitment intact, portfolio expansions underway.
Scrip - February 20, 2026
Novartis divests listed India entity but maintains country commitment intact, portfolio expansions underway.
Scrip - February 20, 2026
Japan Recommends Global-First Conditional Approvals Of Two iPSC Therapies
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.
Scrip - February 20, 2026
Japan has granted the first positive approval recommendations worldwide for two allogenic cell therapies derived from induced pluripotent stem cells, Sumitomo’s raguneprocel for Parkinson’s and Cuorips’ cardiomyocyte patches for heart failure.
Scrip - February 20, 2026
Radiologist Abramson Takes The Reins At Digital Health Center of Excellence
The US FDA has a new digital health head in radiologist Rick Abramson, an AI-industry veteran who is now director of the Digital Health Center of Excellence. Abramson has been an FDA adviser since last summer.
Medtech Insight - February 19, 2026
The US FDA has a new digital health head in radiologist Rick Abramson, an AI-industry veteran who is now director of the Digital Health Center of Excellence. Abramson has been an FDA adviser since last summer.
Medtech Insight - February 19, 2026
Class I Recalls Rose In 2025, Despite Drop In Overall Number
Class I medical device recalls reached record-breaking levels in 2025, according Sedwick’s annual product safety report, with device failure the leading cause.
Medtech Insight - February 19, 2026
Class I medical device recalls reached record-breaking levels in 2025, according Sedwick’s annual product safety report, with device failure the leading cause.
Medtech Insight - February 19, 2026
Olympus To Cut 2,000 Jobs, Revises Guidance As FDA Inspections Weigh On Q3
Olympus released its Q3 2025 earnings on Feb. 13, lowering its full-year revenue outlook by 2% on a constant currency basis. While the company acknowledged continued pressure in the US, management said it expects performance to rebound in Q4.
Medtech Insight - February 19, 2026
Olympus released its Q3 2025 earnings on Feb. 13, lowering its full-year revenue outlook by 2% on a constant currency basis. While the company acknowledged continued pressure in the US, management said it expects performance to rebound in Q4.
Medtech Insight - February 19, 2026
Medtronic Wins FDA Clearance For Stealth AXiS, Targets Spine Robotics Growth
The Stealth AXiS system is designed as an integrated platform that combines robotics, surgical planning and navigation into a single solution for spine procedures.
Medtech Insight - February 19, 2026
The Stealth AXiS system is designed as an integrated platform that combines robotics, surgical planning and navigation into a single solution for spine procedures.
Medtech Insight - February 19, 2026
Telehealth Company Hims & Hers To Acquire Eucalyptus In A Deal Up To $1.15Bn
Hims&Hers announced plans to acquire digital health company Eucalyptus for up to $1.15bn.
Medtech Insight - February 19, 2026
Hims&Hers announced plans to acquire digital health company Eucalyptus for up to $1.15bn.
Medtech Insight - February 19, 2026
Execs On The Move: February 9–13, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 19, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - February 19, 2026
UK Industry Fires Warning Shots Over Cost Burden, Support Levels And Over-Regulation In Market
The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.
Medtech Insight - February 19, 2026
The latest annual UK ABHI survey of medtech industry sentiment on market access, regulatory hurdles and pathways for innovation reveals polarized views and levels of frustration among manufacturers who face ever higher compliance workloads.
Medtech Insight - February 19, 2026
US FDA’s Push For Greater Transparency: What About Advisory Committees?
Posting action packages for rejected products, not just the complete response letters, is a provocative idea, but also a reminder of what the FDA has lost by not holding many advisory committees during the Trump Administration.
HBW Insight - February 20, 2026
Posting action packages for rejected products, not just the complete response letters, is a provocative idea, but also a reminder of what the FDA has lost by not holding many advisory committees during the Trump Administration.
HBW Insight - February 20, 2026
Sandoz Mulls Appeal As US Court Dismisses Amgen Enbrel Antitrust Complaint
Sandoz has told Generics Bulletin that it is mulling further options, including an appeal, after a US court dismissed its antitrust complaint against Amgen over Enbrel. Currently, Sandoz’s Erelzi etanercept biosimilar – approved almost a decade ago – is blocked from launch for a further three years.
Generics Bulletin - February 20, 2026
Sandoz has told Generics Bulletin that it is mulling further options, including an appeal, after a US court dismissed its antitrust complaint against Amgen over Enbrel. Currently, Sandoz’s Erelzi etanercept biosimilar – approved almost a decade ago – is blocked from launch for a further three years.
Generics Bulletin - February 20, 2026
Burn Control And Subcutaneous Focus: OSE’s Bid To Reprice Its Science
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
In Vivo - February 19, 2026
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
In Vivo - February 19, 2026